Esketamine for Adolescents with Depression

A groundbreaking study Presented at the 2023 Annual Meeting of the American Psychiatric Association San Francisco, CA, demonstrates that esketamine nasal spray can rapidly reduce depressive symptoms in adolescents at high risk of suicide. 


Unlike previous antidepressant trials, this study includes a vulnerable patient population that has been traditionally overlooked: adolescents at immediate and imminent risk of suicide. These findings contribute to our understanding of the potential benefits of esketamine and highlight the importance of inclusivity in clinical trials to address the needs of all patient groups. This study was conducted on male or female teenagers between the ages of 12 and 18 who had been diagnosed with Major Depressive Disorder. 


The results of this study revealed a meaningful improvement in depressive symptoms, which was both statistically and clinically significant, observed just 24 hours after the initial administration of pooled Esketamine doses at 56 mg and 84 mg. In comparison to a psychoactive comparator, the use of esketamine demonstrated a clear advantage in alleviating depressive symptoms. Treatment with a psychological intervention (individual cognitive behavioral therapy, interpersonal therapy, family

therapy, psychodynamic psychotherapy) was also required, at least through the initial 8-week Post-Treatment Follow-Up phase.


These findings provide substantial evidence supporting the efficacy of esketamine as a potential treatment option for individuals struggling with depression. By showcasing its rapid action and significant impact, this study contributes to our understanding of the therapeutic potential of esketamine and highlights its superiority over existing psychoactive comparators.


This study indicated that the adolescents experienced a rapid decrease in depressive symptoms, which aligns with similar findings observed in phase 3 studies involving adults with Major Depressive Disorder (MDD) who were dealing with acute suicidal thoughts or behavior. It is noteworthy that there were no new or unexpected safety concerns identified in the adolescent participants, and these observations were consistent with previous trials conducted with adults at risk of suicide. 


These conclusions provide further evidence supporting the effectiveness and safety of the treatment across different age groups, highlighting its potential as a valuable intervention in addressing depression and reducing the risk of suicide in both adolescents and adults with MDD.


Here at Blue Umbrella, we proudly offer Spravato (EsKetamine) as a form of treatment for suicidal ideation. We have seen tremendous improvement in multiple dire cases and are excited to share this innovative and effective treatment option with the community.

References:


Colette Kosik-Gonzalez

MA1


Dong Jing Fu

MD, PhD1*


Li "Nancy" Chen

PhD1


Rosanne Lane

MAS1


Wayne C. Drevets

MD2


Carla M. Canuso

MD1


Janssen Research and Development, LLC

Titusville, NJ | San Diego, CA


Esketamine Nasal Spray versus Psychoactive Comparator for Rapid Reduction of Depressive Symptoms in adolescents at Imminent Suicide Risk, 2023

Child eating a snack indoors, with a thoughtful expression and blurred home background
October 29, 2026
Learn how to help anxious children navigate Halloween fears, sensory overload, and scary situations with supportive strategies that build comfort and confidence.
Hand reaching toward a row of colorful pencils on a white table
October 22, 2026
Learn what OCD really is, how obsessions and compulsions impact daily life, common symptoms to recognize, and when seeking mental health support may help today.
Patient seated on couch, covering face, while clinician in white coat offers support in a counseling session
October 15, 2026
Discover why mental health care is essential, how it impacts daily life, and why seeking support early can help improve overall wellbeing and quality of life.
Person slumped over a desk in a bright office, surrounded by laptop, papers, and plants
October 8, 2026
Learn the differences between stress, burnout, and depression, recognize common symptoms, and understand when mental health support may help you find relief.
Stressed coworkers at a desk, one holding her head, with headline about Sunday anxiety and workplace worries
October 1, 2026
Understand the Sunday Scaries, what causes workweek anxiety, how it affects your sleep and daily life, and when professional mental health support may help.
Hooded person sits on the floor with head in hands as black scribbles burst from the wall nearby
September 24, 2026
Learn how negative self-talk affects emotional wellness and discover ways to develop healthier thought patterns, build self-compassion, and improve mental health.
Crowded group of people in white shirts looking down at smartphones indoors
September 17, 2026
Learn how social media affects mental health, from anxiety and comparison to loneliness, and discover ways to create healthier online habits and digital boundaries.
Woman sitting apart and looking down while a group chats on a couch in the background
September 10, 2026
Learn how social isolation affects mental health, including loneliness, anxiety, and depression, and discover ways to rebuild meaningful connections and support.
Person sitting on outdoor steps, knees hugged to chest, head resting on arms, in warm sunlight.
September 3, 2026
Discover how anxiety affects the body, why physical symptoms occur, and how understanding the mind-body connection can help you manage stress and improve wellbeing.
Blue line drawing of a head with a stethoscope examining the brain
August 27, 2026
Discover why consistency matters in mental health treatment and how regular care, healthy routines, and ongoing support can help improve long-term wellness.